New York · Nonprofit
BONE MARROW & CANCER FOUNDATION INC
BONE MARROW & CANCER FOUNDATION INC (New York) receives grants from 105 organizations whose IRS filings report $4,928,906 to it, the largest being FIDELITY INVESTMENTS CHARITABLE GIFT FUND ($1,651,135). 51 of them have funded it in more than one year, and 52% of the money arrives through donor-advised or pass-through sponsors rather than from an institution directly.
- Revenue FY2024
- $1.6M
- Funders on record
- 105
- Grants received
- $4.9M
- Net assets
- $1.3M
What Bone Marrow & Cancer Foundation Inc does
Mission
The bone marrow & cancer foundation, founded in 1992, is dedicated to improving the quality of life for cancer and transplant patients and their families by providing vital financial assistance, comprehensive resources, educational information, physician referrals, and emotional support programs. The bone marrow & cancer foundation is the only organization of its kind that does not limit assistance to a specific disease, type of transplant, or age range. All of the foundation's programs and services are offered to patients and their families free of charge.
As stated on its FY2024 Form 990.
Program
Guided by a medical advisory board of nationally-recognized cancer specialists and working with hospitals across the united states, the bone marrow & cancer foundation is the only organization of its kind that does not limit assistance to a specific disease, type of transplant or age range. For the past 31 years, the foundation has connected patients and their families with the services they need-from diagnosis through survivorship-to make effective decisions about treatment and its aftermath. All of the foundation's programs and services are offered to patients and their families free of charge. Our programs include:lifeline fund provides financial support for transplant patients to help cover the costs of donor searches, medications, home and child care services, medical equipment, transportation, cord blood banking, housing costs and other expenses associated with the transplant. Health insurance often does not cover these vital support services, and many patients cannot afford them on their own. One-to-one funds enable patients to reach out to family, friends, and social networks for financial support. A one-to-one fund can be created in minutes and promoted through social…
$1,468,101 spentof which $481,949 as grants100% of program spending
The program described on its FY2024 Form 990. Program spending in total: $1,468,101.
The organization over time
Each line starts at 100 in 2017, so what you read is the shape rather than the size: 150 means half as much again as 2017, 50 means half. The number beside each label in the key is where it ended. The shaded band is where the middle 50% of its peers' revenue would sit, given their growth.
Balance sheet
Total assets and total liabilities at each year end, in dollars. The largest one-year move in total assets was 2020 to 2021, from $1.3M to $2.3M (+81%).
How it's funded, over time
Each bar is one year's revenue split into where it came from, and every bar is the same height — these are shares, not amounts, so a year that raised twice as much looks the same size. Hover a bar for the split.
Government-grant reliance: 2021 10%. Grants only. Government contracts and fees sit inside program revenue.
95% of BONE MARROW & CANCER FOUNDATION INC’s revenue is contributions — more reliant on donations than three-quarters of its peers (51% for the typical peer).
Surplus & reserves
Operating surplus or deficit each year, and months of liquidity in hand. 3 of the last 7 reported years ran a deficit.
reserve
Leadership and staff
The officers, directors, trustees and key employees listed on each return. Joined and no longer listed compare each filing with the year before, matching people by surname and first initial; a year after a gap, or a roster under three people, has no comparison.
Board chair
Robert Fishman
Chairman
As listed on its FY2024 Form 990.
Who funds it, year by year
2017 → 2023: the base broadened from 26 funders to 32 funders, grant income rose $251k → $749k.
20 of 105 of your funders are donor-advised or pass-through sponsors (tagged DAF) — 52% of grant dollars received. That money is really individual donors directing a sponsor; the institutions to cultivate are the non-DAF funders.
From the IRS filings of BONE MARROW & CANCER FOUNDATION INC’s funders (the co-funder graph). Top 30 of 105 funders by total. Association, not causation. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
How concentrated its funding is
BONE MARROW & CANCER FOUNDATION INC leans on a few funders — its largest provides 33% of grant income and the top three 55%; half comes from just 2 funders.
the vertical line marks half of all grant income — 2 funders to its left
54% of the income these shares are computed over arrives through pass-through sponsors or from payers whose filings do not say what kind of payment it is. Concentration is still measured over all of it, because the money is real; what it does not support is a claim about how many institutions have chosen to fund BONE MARROW & CANCER FOUNDATION INC.
Largest funder’s share by year: 2017 44% · 2018 37% · 2019 44% · 2020 30% · 2021 34% · 2022 33% · 2023 37% — diversifying over time.
“Effective funders” = inverse Herfindahl index (1 / Σ shareᵢ²) — the number of equal-sized funders that would give the same concentration. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
How long its funders stay
28% of BONE MARROW & CANCER FOUNDATION INC's funders are still giving 3 years after their first grant; 49% give in more than one year at all.
Share of funders still giving k years after their first recorded grant, pooled across every acquisition cohort. A funder counts as retained in a year only if it made a grant that year. Measured to FY2023, the last fiscal year that has finished arriving — a funder cannot be counted as lapsed in a year most filers have not reached.
Where its funders are
52% of BONE MARROW & CANCER FOUNDATION INC's grant income arrives through donor-advised or pass-through sponsors, whose addresses record where the money is held rather than where the donor is. Of the $2.4M that is directly attributable, 65% of it comes from New York funders.
In-state vs out-of-state, by year
Funder states come from each funder’s own filing. $2.5M arriving through sponsors registered in 12 states is excluded from the map and the split above: a sponsor holds money on a donor’s behalf, so its registered address would place those dollars somewhere no donor need ever have been. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
Against its field
BONE MARROW & CANCER FOUNDATION INC is better cushioned than half of the 8,126 health nonprofits its size.
this organization peer median middle 50% of peers· 8,126 health nonprofits $1M–$10M, FY2024
Organizations like BONE MARROW & CANCER FOUNDATION INC
Organizations whose mission and program text most resemble this one, by semantic similarity over every organization in the US filings — the closest peers, and often the clearest route to shared or prospective funders.
In New York
Nationally
Read directly from this organization’s own Form 990, as neutral context.
Where the money goes
77% of spending goes to programs.
Governance
Public support
91%
Share of support from the public (Schedule A) — the basis for its public-charity status.
Footprint & structure
Files a return copy in 1 state
Screen this organization
A dated, signed PDF of the compliance screen for BONE MARROW & CANCER FOUNDATION INC: IRS status (Business Master File, Publication 78, auto-revocation), the OFAC sanctions lists, the Internal Revenue Bulletin, and California registration, with the Rev. Proc. 2018-32 §8.01 reliance elements stated element by element. Generated from the current files at the moment you download it.
Screens are triage, not determinations; a source that cannot be read reports not screened, never clear. Screen this nonprofit · How the screen works · on the API as GET /api/screening/{ein}?format=pdf
Questions and answers
- Who funds BONE MARROW & CANCER FOUNDATION INC?
- BONE MARROW & CANCER FOUNDATION INC (New York) receives grants from 105 organizations whose IRS filings report $4,928,906 to it, the largest being FIDELITY INVESTMENTS CHARITABLE GIFT FUND ($1,651,135). 51 of them have funded it in more than one year, and 52% of the money arrives through donor-advised or pass-through sponsors rather than from an institution directly.
- How many funders does BONE MARROW & CANCER FOUNDATION INC have?
- IRS filings report 105 organizations giving $4,928,906 in grants to BONE MARROW & CANCER FOUNDATION INC, 51 of which have funded it in more than one year.
- Who is the largest funder of BONE MARROW & CANCER FOUNDATION INC?
- FIDELITY INVESTMENTS CHARITABLE GIFT FUND is the largest funder on record, with $1,651,135 in grants. The full list of funders is on this page.
- How can an organization like BONE MARROW & CANCER FOUNDATION INC find more funders?
- Start with the funders already giving here, then look at the foundations that back similar organizations in New York. The funding by cause and by state pages list the largest funders for a given area and how to approach them.
Play a game about who funds Bone Marrow & Cancer →
These figures are read directly from IRS Form 990 / 990-PF e-file XML: this organization’s own return for FY2024 (financials across 2017–2024), and the filings of 105 funders that report grants to it. “On record” means captured in the filings we have parsed — a funder that does not e-file, or whose grant detail is not itemized, will not appear. Filings run roughly 12–24 months behind. Trends on this page end at FY2023, the last fiscal year that has finished arriving; later years are shown and marked, and move no figure. Data on this page was exported October 22, 2026. What this page cannot tell you · view filing